Centrient Pharmaceuticals joins UNGC
Reinforcing commitment to ethical and sustainable growth
Reinforcing commitment to ethical and sustainable growth
The agreement complements other PPAs for Sandoz production sites globally
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
This strategic investment strengthens Cohance's integrated oligonucleotide platform
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025
Subscribe To Our Newsletter & Stay Updated